Literature DB >> 16901919

Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy.

Sarah X Zhang1, Joshua J Wang, Guoquan Gao, Kyoungmin Parke, Jian-xing Ma.   

Abstract

It has been shown that the balance between vascular endothelial growth factor (VEGF), a major angiogenic stimulator, and pigment epithelium-derived factor (PEDF), a potent angiogenic inhibitor, is critical for the regulation of vascular permeability and angiogenesis. However, the regulation of the balance is largely unclear. The present study demonstrated that there is a reciprocal interaction between VEGF and PEDF in the retina. PEDF significantly decreased VEGF expression in both retinal capillary endothelial cells (RCEC) and Müller cells. This PEDF effect was confirmed in the retina of rats with oxygen-induced retinopathy. Silencing of the PEDF gene by siRNA in Müller cells resulted in a significant upregulation of VEGF expression at both the RNA and protein levels, suggesting that PEDF is an endogenous negative regulator of VEGF. The further study of the mechanism showed that PEDF inhibited hypoxia-induced increases in VEGF promoter activity, HIF-1 nuclear translocation and mitogen activated protein kinase phosphorylation. These results suggest that PEDF inhibits VEGF expression at the transcriptional level. In addition, PEDF effectively inhibited VEGF binding to RCEC. Moreover, in vitro receptor-binding assay demonstrated that PEDF competed with VEGF for binding to VEGF receptor 2, which may represent a new mechanism for PEDF activity. On the other hand, VEGF significantly downregulated PEDF expression in RCEC, but not in retinal Müller cells, suggesting a VEGF receptor-mediated process. These results suggest that the reciprocal regulation between VEGF and PEDF may play a role in angiogenic control. The decrease in PEDF levels in the retina is at least partially responsible for the increase in VEGF expression and subsequent vascular leakage and neovascularization in diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16901919     DOI: 10.1677/jme.1.02008

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  85 in total

1.  Increased angiogenic factors associated with peripheral avascular retina and intravitreous neovascularization: a model of retinopathy of prematurity.

Authors:  Steven J Budd; M Elizabeth Hartnett
Journal:  Arch Ophthalmol       Date:  2010-05

2.  A therapeutic strategy for choroidal neovascularization based on recruitment of mesenchymal stem cells to the sites of lesions.

Authors:  Hui-Yuan Hou; Hong-Liang Liang; Yu-Sheng Wang; Zhao-Xia Zhang; Bai-Ren Wang; Yuan-Yuan Shi; Xiao Dong; Yan Cai
Journal:  Mol Ther       Date:  2010-07-20       Impact factor: 11.454

Review 3.  Angiogenesis in diabetes and obesity.

Authors:  Rui Cheng; Jian-xing Ma
Journal:  Rev Endocr Metab Disord       Date:  2015-03       Impact factor: 6.514

4.  Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization.

Authors:  Kyoungmin Park; Ji Jin; Yang Hu; Kevin Zhou; Jian-xing Ma
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 5.  Involvement of Müller glial cells in epiretinal membrane formation.

Authors:  Andreas Bringmann; Peter Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-05       Impact factor: 3.117

6.  Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients.

Authors:  Alicia J Jenkins; Dongxu Fu; Madona Azar; Julie A Stoner; Derrick G Kaufman; Sarah Zhang; Richard L Klein; Maria F Lopes-Virella; Jian-Xing Ma; Timothy J Lyons
Journal:  J Diabetes Complications       Date:  2014-01-17       Impact factor: 2.852

7.  Retinal angiogenesis in the Ins2(Akita) mouse model of diabetic retinopathy.

Authors:  Zongchao Han; Junjing Guo; Shannon M Conley; Muna I Naash
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

8.  Antipermeability function of PEDF involves blockade of the MAP kinase/GSK/beta-catenin signaling pathway and uPAR expression.

Authors:  Jinling Yang; Elia J Duh; Ruth B Caldwell; M Ali Behzadian
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

9.  Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4.

Authors:  Jingming Li; Joshua J Wang; Qiang Yu; Kai Chen; Kalyankar Mahadev; Sarah X Zhang
Journal:  Diabetes       Date:  2010-03-23       Impact factor: 9.461

10.  The anti-angiogenic factor PEDF is present in the human heart and is regulated by anoxia in cardiac myocytes and fibroblasts.

Authors:  Kathrin Rychli; Christoph Kaun; Philipp J Hohensinner; Adrian J Dorfner; Stefan Pfaffenberger; Alexander Niessner; Michael Bauer; Wolfgang Dietl; Bruno K Podesser; Gerald Maurer; Kurt Huber; Johann Wojta
Journal:  J Cell Mol Med       Date:  2010-01       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.